| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 07/03/2002 | EP1218011A1 Gallium complexes of 3-hydroxy-4-pyrones to treat infection by intracellular prokaryotes, dna viruses and retroviruses |
| 07/03/2002 | EP1218009A1 Quetiapine granules |
| 07/03/2002 | EP1217993A2 Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
| 07/03/2002 | EP1217992A1 Coated solid dosage forms |
| 07/03/2002 | EP1217990A1 Cationic dosper virosomes |
| 07/03/2002 | EP1217989A1 Liposome-entrapped dna oral vaccines |
| 07/03/2002 | EP1217988A1 Proteinic drug delivery system using membrane mimetics |
| 07/03/2002 | EP1217975A1 Using quaternary ammonium salts for transdermal drug delivery |
| 07/03/2002 | EP1217902A1 Nutritional compositions which contain non-digestible polysaccharides and use thereof to reduce transport through tight junctions |
| 07/03/2002 | EP1146860A4 Polymeric delivery agents and delivery agent compounds |
| 07/03/2002 | EP1131062A4 Injectable propofol formulations |
| 07/03/2002 | EP1109536B1 New solid dose form of nanoparticulate naproxen |
| 07/03/2002 | EP1063978A4 Method of treating neuroma pain |
| 07/03/2002 | EP0971729B1 Therapeutic powder formulation for pulmonary administration, containing crystalline insulin |
| 07/03/2002 | EP0942738B1 Polyethylene glycol esters of polyunsaturated fatty acids |
| 07/03/2002 | EP0863769B1 Glycoconjugates as virus cell adhesion inhibitors |
| 07/03/2002 | EP0698393B1 3-l-MENTHOXY-PROPANE-1, 2-DIOL AS SOLUBILIZING AGENT AND EXTERNAL PREPARATION CONTAINING THE SAME |
| 07/03/2002 | EP0661045B1 Sustained-release hydrogel preparation |
| 07/03/2002 | EP0637248B1 Pharmaceutical composition containing cyclosporin derivative |
| 07/03/2002 | CN1357048A Enhanced prodrug activation |
| 07/03/2002 | CN1357023A Controlled release polyacrylic acid granules and process for preparing same |
| 07/03/2002 | CN1356975A Amorphous nitric esters and their pharmaceutical compsns. |
| 07/03/2002 | CN1356910A Model membrane systems |
| 07/03/2002 | CN1356907A Fish serine proteinases and their pharmaceutical and cosmetic use |
| 07/03/2002 | CN1356901A Pharmaceutical compsn. and process for its prepn. |
| 07/03/2002 | CN1356896A Anesthetic compsn. for intravenous injection comprising propofol |
| 07/03/2002 | CN1356895A Microreservoir system on basis of polysiloxanes and ambiphilic solvents |
| 07/03/2002 | CN1356894A Transdermal therapeutic system (TTS) contg. tolterodine |
| 07/03/2002 | CN1356893A New formulation |
| 07/03/2002 | CN1356892A Use of biodegradable microspheres for delivery of anticancer for treatment of glioblastoma |
| 07/03/2002 | CN1356887A Niacinamide compsns. with reduced tack |
| 07/03/2002 | CN1356397A Process for preparing powder containing maltose alcohol crystal grains |
| 07/03/2002 | CN1356259A Modified nano silicon particles |
| 07/03/2002 | CN1356143A Emulsion-type lubricant and its application in medical rubber product |
| 07/03/2002 | CN1356102A Taste Masked medicine particles |
| 07/02/2002 | US6414050 Biofunctional polymers prepared in supercritical fluid |
| 07/02/2002 | US6414037 Pharmaceutical formulations of resveratrol and methods of use thereof |
| 07/02/2002 | US6414033 Determination ph; buffer solution |
| 07/02/2002 | US6414032 Anti-infective compositions for treating disordered tissue such as cold sores |
| 07/02/2002 | US6414029 Antidiabetic agents |
| 07/02/2002 | US6414028 Mixture with skin penetration intensifier, polysaccharide gum and buffer |
| 07/02/2002 | US6413988 Prucalopride oral solution |
| 07/02/2002 | US6413950 Topical application; skin disorders |
| 07/02/2002 | US6413945 Gastro-specific prodrugs |
| 07/02/2002 | US6413941 Polymer composition for delivering a nucleic acid or derivative thereof |
| 07/02/2002 | US6413934 Biotin binding zones |
| 07/02/2002 | US6413770 NL4 tie ligand homologue nucleic acid |
| 07/02/2002 | US6413763 Method of removing gas from a site using gas vesicles of cells |
| 07/02/2002 | US6413735 Method of screening for a modulator of angiogenesis |
| 07/02/2002 | US6413715 β(1-3)-glucan diagnostic assays |
| 07/02/2002 | US6413552 Topically applied creatine containing composition |
| 07/02/2002 | US6413550 Proteinoid carriers and methods for preparation and use thereof |
| 07/02/2002 | US6413549 Freeze drying |
| 07/02/2002 | US6413544 Sandwich liposome comprises biologically active agents internalized between two bilomellar liposomes; 1,2-bis(oleoyloxy)-3-(trimethylammonio)-propane chloride, cholesterol or cholesterol derivative |
| 07/02/2002 | US6413543 Phosphatidyl oligoglycerols |
| 07/02/2002 | US6413540 For eyes |
| 07/02/2002 | US6413539 Block polymer |
| 07/02/2002 | US6413537 Nystatin formulation having reduced toxicity |
| 07/02/2002 | US6413536 High viscosity liquid controlled delivery system and medical or surgical device |
| 07/02/2002 | US6413533 Administering antiestrogen |
| 07/02/2002 | US6413507 Modified polyether |
| 07/02/2002 | US6413503 Use of cyclic enamines as light protection agents |
| 07/02/2002 | US6413494 Composition and pharmaceutical dosage form for colonic drug delivery using polysaccharides |
| 07/02/2002 | US6413463 Process for producing hard capsule |
| 07/02/2002 | CA2333528C A stabilized antihistamine syrup containing aminopolycarboxylic acid as stabilizer |
| 07/02/2002 | CA2147224C Partially acylated .beta.-cyclodextrins |
| 07/02/2002 | CA2123696C Antitumor vaccines |
| 07/02/2002 | CA2061703C Formulations containing hyaluronic acid |
| 06/27/2002 | WO2002050100A2 Diaminodicarboxylic acid: peptide-based gemini surfactant compounds used for drug delivery |
| 06/27/2002 | WO2002050097A2 Anti-allergic complex molecules |
| 06/27/2002 | WO2002050089A1 Method for purification of lactose |
| 06/27/2002 | WO2002049714A2 Electrically responsive promoter system |
| 06/27/2002 | WO2002049676A2 Compositions containing inclusion complexes |
| 06/27/2002 | WO2002049675A1 Compositions of estrogen-cyclodextrin complexes |
| 06/27/2002 | WO2002049674A1 Cyclodextrin-drospirenone inclusion complexes |
| 06/27/2002 | WO2002049673A2 Conjugates of erythropoietin (pep) with polyethylene glycol (peg) |
| 06/27/2002 | WO2002049672A2 Conjugates of antibodies and anticancer drugs |
| 06/27/2002 | WO2002049671A1 Recombinant serum albumin for use in cleansing or dermatological products for skin or hair |
| 06/27/2002 | WO2002049669A2 Electrically responsive promoter system |
| 06/27/2002 | WO2002049667A2 Vaccine for treating nicotine addiction |
| 06/27/2002 | WO2002049666A2 Mycoplasma hyopneumoniae bacterin vaccine |
| 06/27/2002 | WO2002049654A1 Shark meat extract |
| 06/27/2002 | WO2002049646A1 Therapeutic combination of amlodipine and benazepril/benazeprilat |
| 06/27/2002 | WO2002049645A1 Therapeutic combination of amlodipine and benazepril |
| 06/27/2002 | WO2002049638A1 Medicinal granular preparation containing branched amino acids |
| 06/27/2002 | WO2002049631A1 Propofol formulation with enhanced microbial inhibition |
| 06/27/2002 | WO2002049624A2 Novel pharmaceutical compositions based on anticholinergic agents and dopamine agonists |
| 06/27/2002 | WO2002049622A2 Transdermal system containing a novel high potency progestagen |
| 06/27/2002 | WO2002049621A1 Enteric-coated drug formulations and their manufacture |
| 06/27/2002 | WO2002049620A2 Induced phase transition method for the production of microparticles containing hydrophobic active agents |
| 06/27/2002 | WO2002049619A2 Induced phase transition method for the production of microparticles containing hydrophilic active agents |
| 06/27/2002 | WO2002049617A2 Self forming, thermodynamically stable liposomes and their applications |
| 06/27/2002 | WO2002049616A1 Pharmaceutical aerosol formulation |
| 06/27/2002 | WO2002049614A2 Intraocular irrigating solution having improved flow characteristics |
| 06/27/2002 | WO2002049609A1 Ionophore antibiotic formulations |
| 06/27/2002 | WO2002049606A2 Transdermal systems (tds) that contain inhibitors of phosphodiesterase iv |
| 06/27/2002 | WO2002049575A2 Method and composition for the treatment of diabetic neuropathy |
| 06/27/2002 | WO2002049573A2 Novel in-situ forming controlled release microcarrier delivery system |
| 06/27/2002 | WO2002049552A2 Solution for removing cataracts via liquefracture |
| 06/27/2002 | WO2002049501A2 Local regional chemotherapy and radiotherapy using in situ hydrogel |